Xin LI, Xinglin YI, Yan CHEN, et al. Construction of predictive model for early allograft dysfunction after liver transplantation[J]. Journal of Army Medical University, 2024, 46(7): 746-752.
DOI:
Xin LI, Xinglin YI, Yan CHEN, et al. Construction of predictive model for early allograft dysfunction after liver transplantation[J]. Journal of Army Medical University, 2024, 46(7): 746-752. DOI: 10.16016/j.2097-0927.202312009.
Construction of predictive model for early allograft dysfunction after liver transplantation
To analyze the factors related to early allograft dysfunction (EAD) after liver transplantation and to construct a predictive model.
Methods
2
A total of 375 patients who underwent liver transplantation in our hospital from December 2008 to December 2021 were collected
including 90 patients with EAD and 266 patients without EAD.Thirty items of baseline data for the 2 groups were compared and analyzed.After grouping in a ratio of 7:3
univariate and multivariate logistic regression analyses were used in the training set to evaluate the factors related to EAD and construct a nomogram.Receiver operating characteristic (ROC) curve
decision curve analysis (DCA)
sensitivity
specificity
positive predictive value
negative predictive value
Kappa value and other indicators were used to evaluate the model performance.
Results
2
The incidence of EAD after liver transplantation was 24%.Multivariate logistic regression analysis showed that preoperative tumor recurrence history (
OR
=3.15
95%
CI
: 1.28~7.77
P
=0.013) and operation time (
OR
=1.22
95%
CI
: 1.04~1.42
P
=0.015) were related to the occurrence of EAD after surgery.After predicting the outcome according to the cut-off point of 0.519 identified by the Youden index
the model performance in the both training set and validation set was acceptable.DCA suggested the model has good clinical applicability.
Conclusion
2
The risk factors for EAD after liver transplantation are preoperative tumor recurrence history and operation time
and the established model has predictive effect on prognosis.
CHEN J, SHEN T, LI J H, et al . Clinical practice guidelines for liver transplantation for liver cancer in China(2021 edition)[J ] . Pract J Organ Tr ansplant Electron Version, 2022, 10(6): 481-489, 480.
KWONG A J, KIM W R, LAKE J R, et al . OPTN/SRTR 2019 annual data report: liver[J ] . Am J Transplant, 2021, 21(Suppl 2): 208-315. DOI: 10.1111/ajt.16494.
OLTHOFF K M, KULIK L, SAMSTEIN B, et al . Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors[J ] . Liver Transpl, 2010, 16(8): 943-949. DOI: 10.1002/lt.22091.
NAM K W, KWON H M, JEONG H Y, et al . Pooled cohort risk equation and subclinical cerebrovascular diseases[J ] . Euro J Neurology, 2020, 27(5): 793-799. DOI: 10.1111/ene.14155.
POSKUS T, SABONYTE-BALSAITIENE Z, JAKUBAUSKIENE L, et al . Preventing hemorrhoids during pregnancy: a multicenter, randomized clinical trial[J ] . BMC Pregnancy Childbirth, 2022, 22(1): 374. DOI: 10.1186/s12884-022-04688-x.
MENG H P, DONG H G, YAN L N. Risk factors of early allograft dysfunction after liver trans-plantation[J]. Chin J Curr Adv Gen Surg, 2022, 25(6): 436-438, 460. DOI: 10.3969/j.issn.1009-9905.2022.06.005.
ADAM R, AZOULAY D, CASTAING D, et al . . Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?[J ] . Eur Surg, 2004, 36(1): 56-57. DOI: 10.1007/s10353-004-0038-y.
WIESNER R, EDWARDS E, FREEMAN R, et al . Model for end-stage liver disease(MELD) and allocation of donor livers[J ] . Gastroenterology, 2003, 124(1): 91-96. DOI: 10.1053/gast.2003.50016.
WIESNER R. MELD and PELD: application of survival models to liver allocation[J]. Liver Transplant, 2001, 7(7): 567-580. DOI: 10.1053/jlts.2001.25879.
AVOLIO A W, FRANCO A, SCHLEGEL A, et al . Development and validation of a comprehensive model to estimate early allograft failure among patients requiring early liver retransplant[J ] . JAMA Surg, 2020, 155(12): e204095. DOI: 10.1001/jamasurg.2020.4095.
IJTSMA A J C, VAN DER HILST C S, DE BOER M T, et al . The clinical relevance of the anhepatic phase during liver transplantatio n[J ] . Liver Transpl, 2009, 15(9): 1050-1055. DOI: 10.1002/lt.21791.
ESCH J S A 2nd, KNOEFEL W T, KLEIN M, et al . Portal application of autologous CD133 + bone marrow cells to the liver: a novel concept to support hepatic regeneration[J ] . Stem Cells, 2005, 23(4): 463-470. DOI: 10.1634/stemcells.2004-0283..
GU J T, SUN P, ZHAO H L, et al . Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice[J ] . Crit Care, 2011, 15(3): R153. DOI: 10.1186/cc10283.
MA J B, CHEN Q, LI J J, et al . Dexmedetomidine-mediated prevention of renal ischemia-reperfusion injury depends in part on cholinergic anti-inflammatory mechanisms[J ] . Anesth Analg, 2020, 130(4): 1054-1062. DOI: 10.1213/ane.0000000000003820.
HUANG D B, SHEN Y N, ZHANG W, et al . A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study[J ] . BMC Cancer, 2021, 21(1): 280. DOI: 10.1186/s12885-021-07938-x.
GUO D D, WANG H F, LIU J, et al . Prediction of chronic kidney dise ase after orthotopic liver transplantation: development and validation of a nomogram model[J ] . BMC Nephrol, 2022, 23(1): 33. DOI: 10.1186/s12882-021-02650-1.
AGRAWAL D, SAIGAL S. Early allograft dysfunction after living donor liver transplantation—current concepts and future directions[J]. Liver Transplant, 2023, 29(8): 871-884. DOI: 10.1097/lvt.0000000000000173.
ITO T, NAINI B V, MARKOVIC D, et al . Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients[J ] . Am J Transplant, 2021, 21(2): 614-625. DOI: 10.1111/ajt.16219.
NARAYAN R R, ABADILLA N, YANG L F, et al . Artificial intelligence for prediction of donor liver allograft steatosis and early post-transplantation graft failure[J ] . HPB, 2022, 24(5): 764-771. DOI: 10.1016/j.hpb.2021.10.004.
OHARA S, MACDONOUGH E, EGBERT L, et al . Decreasing significance of early allograft dysfunction with rising use of nonconventional donors[J ] . Medicina, 2022, 58(6): 821. DOI: 10.3390/medicina58060821.